^
Association details:
| Biomarker: | FGFR3 positive |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | rogaratinib (BAY 1163877) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A NOVEL MRNA-BASED PATIENT SELECTION STRATEGY IDENTIFIES FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) INHIBITOR-SENSITIVE TUMORS: RESULTS FROM ROGARATINIB PHASE-1 STUDY
Excerpt:
Seventy two FGFR-positive patients were treated with rogaratinib, with 63 evaluable for response. Clinical responses were observed in tumor types not previously associated with FGFR alterations, including a partial remission (PR) in a patient with a FGFR1 mRNA-positive adenoid cystic carcinoma of the tongue and a PR in a FGFR3 mRNA-positive head and neck squamous cell carcinoma patient.
DOI:
10.1093/annonc/mdx367
